ACAD
31.33
-0.37
-1.17%
AEMD
0.26
+0.00
+0.79%
APRI
1.45
+0.23
+19.10%
ARNA
4.7
-0.07
-1.47%
ATEC
1.29
-0.03
-2.27%
CFN
59.65
-0.09
-0.15%
CNAT
5.95
-0.14
-2.35%
CRXM
0.2
0.00
0.00%
CYTX
0.48
-0.02
-4.71%
DXCM
61.24
-1.08
-1.73%
GNMK
13.06
-0.45
-3.33%
HALO
14.41
-0.07
-0.48%
ILMN
201.72
-1.53
-0.75%
INNV
0.25
+0.05
+25.01%
INO
8.71
-0.23
-2.57%
ISCO
0.06
0.00
-5.67%
ISIS
70.4
-2
-2.76%
LGND
58.19
-0.38
-0.64%
LPTN
2.94
0.00
0.00%
MBVX
1.1
-0.01
-0.90%
MEIP
3.66
-0.03
-0.81%
MNOV
3.73
+0.27
+7.80%
MRTX
21.11
+0.13
+0.62%
MSTX
0.46
+0.00
+1.08%
NBIX
33.06
-0.48
-1.42%
NUVA
46.9
-0.03
-0.06%
ONCS
0.39
0.00
-1.14%
ONVO
6.41
-0.18
-2.73%
OREX
5.56
-0.11
-1.94%
OTIC
32.98
-1.44
-4.18%
QDEL
24.7
-0.26
-1.04%
RCPT
112.92
-3.77
-3.23%
RGLS
17.93
-0.97
-5.13%
RMD
64.37
-0.83
-1.27%
SCIE
0.01
+0.00
+1.68%
SPHS
0.47
-0.02
-3.72%
SRNE
10.23
-0.39
-3.66%
TROV
6.11
+0.16
+2.69%
VICL
1.02
-0.01
-0.97%
VOLC
17.98
+0.01
+0.06%
ZGNX
1.38
-0.01
-0.72%
Home » Archive by Category

Syndication

Enzymes Believed to Promote Cancer Actually Suppress Tumors

January 22, 2015 – 10:00 am | Edit Post

Upending decades-old dogma, a team of scientists at the University of California, San Diego School of Medicine say enzymes long categorized as promoting cancer are, in fact, tumor suppressors and that current clinical efforts to develop inhibitor-based drugs should instead focus on restoring the enzymes’ activities.

Suspected cancer promoter actually suppresses tumors

January 22, 2015 – 10:00 am | Edit Post

Protein kinase C inhibits cancer, mutants promote it, UCSD-led study finds.

Suspected cancer promoter actually suppresses tumors

January 22, 2015 – 10:00 am | Edit Post

Protein kinase C inhibits cancer, mutants promote it, UCSD-led study finds.

Enzymes Believed to Promote Cancer Actually Suppress Tumors

January 22, 2015 – 10:00 am | Edit Post

Upending decades-old dogma, a team of scientists at the University of California, San Diego School of Medicine say enzymes long categorized as promoting cancer are, in fact, tumor suppressors and that current clinical efforts to develop inhibitor-based drugs should instead focus on restoring the enzymes’ activities.

Neuwrite SD: Present you vs. Future you

January 22, 2015 – 8:00 am | Edit Post

It’s almost the end of January. How are your New Year’s Resolutions holding up? If you haven’t stuck to them, you’re not alone. In fact, you’re in the majority. There are many reasons we don’t meet our well-intentioned goals to go to the gym more, quit smoking, or go to bed earlier at night. One… More…

Researcher Associate (mira mesa)

January 22, 2015 – 7:39 am | Edit Post

Description
America Diagnostics(ADX) is a startup company, mainly focusing on developing and manufacturing cancer diagnosis kits. We are currently looking for a Research Associate with certain skill sets to join our research team. Primary responsibi […

Takeda California (TCAL) Site Procurement Head – Takeda Pharmaceuticals – San Diego, CA

January 22, 2015 – 7:06 am | Edit Post
Takeda California (TCAL) Site Procurement Head – Takeda Pharmaceuticals –  San Diego, CA

Provides leadership for the TCAL procurement planning process, managing initiatives effectively with all functions in TCAL as well as with Global Procurement….
From Takeda Pharmaceuticals – 22 Jan 2015 14:06:07 GMT
– View all…

Celebrating Freedom through Education

January 22, 2015 – 7:00 am | Edit Post

Nearly 200 UC San Diego volunteers gathered at Howard Pence Elementary School on Sunday to revitalize the school’s garden, paint murals on the playground and much more. The service project, held as part of the campus’s annual Martin Luther King, Jr. Day of Service, was organized by Volunteer50 and the Center for Student Involvement to educate students about the impact they can make in the local community. Following the Day of Service, about 500 campus members represented UC San Diego in the annual Martin Luther King, Jr. Parade, celebrating “Freedom Through Education.”

Cypher Genomics and Sequenom Announce Development Agreement

January 22, 2015 – 5:00 am | Edit Post
Cypher Genomics and Sequenom Announce Development Agreement

Sequenom to apply Cypher’s Mantis technology for advanced genome interpretation in NIPT

SAN DIEGO, Jan. 22, 2015 /PRNewswire/ — Cypher Genomics, Inc., the leading genome informatics company, and Sequenom, Inc. (NASDAQ: SQNM), the leading molecular diagnostics company, today announced a development agreement for next generation noninvasive prenatal tests (NIPT). Through this agreement, Sequenom will utilize Cypher’s genome interpretation technology, called Mantis™, to advance analysis of clinically-relevant fetal sub-chromosomal variants detected in maternal blood. Often not detected until after birth, sub-chromosomal variants comprise greater than 50 percent of rare chromosomal abnormalities beyond the more common aneuploidies and are associated with significant risks of morbidity and mortality.

“We are excited to announce this development agreement with Sequenom, the pioneer of noninvasive prenatal testing,” said Adam Simpson, president and COO of Cypher Genomics. “We have been working closely with Sequenom to validate our automated Mantis technology to classify clinically-relevant sub-chromosomal genomic structural variations, such as copy-number variations (CNVs), in circulating fetal DNA from maternal blood samples, which may have applications in the development of a new, more comprehensive NIPT offering.”

Sequencing-based NIPT has been largely focused on whole chromosome events, such as aneuploidies and trisomies. Sub-chromosomal structural variations, such as microdeletions and microduplications or CNVs, which may occur de novo, are more difficult to detect and classify but represent a larger proportion of clinically relevant abnormalities. The physical boundaries of CNVs implicated in similar diseases can vary greatly, creating a substantial challenge in accurately classifying the pathogenicity of these structural variations for use in NIPT. As an automated and scalable solution, Cypher’s proprietary Mantis technology can help overcome the genomic interpretation challenge and can potentially support Sequenom’s development of a next generation NIPT offering.

“Given the clinical relevance and frequency of microdeletions and microduplications in the general population, detecting and classifying sub-chromosomal genomic variations would broaden the clinical utility of our prenatal testing offerings,” said Dirk van den Boom, Ph.D., chief scientific and strategy officer of Sequenom. “In our continued effort to advance pregnancy care, next generation NIPT offerings will expand the opportunity for physicians to provide parents with more comprehensive information to improve pediatric outcomes.”

Dr. van den Boom concluded, “We have been impressed with the performance of Cypher’s industry-leading Mantis technology in our research validation studies, and we look forward to advancing our collaboration with Cypher Genomics as we develop a next generation NIPT offering and expand into new areas outside of prenatal testing.”

About Sequenom
Sequenom, Inc. (NASDAQ: SQNM) is committed to enabling healthier lives through the development of innovative products and services. The company serves patients and physicians by providing early patient management information. To learn how Sequenom is interpreting the genome to improve your life, visit www.sequenom.com and follow @SequenomLabs.

About Cypher Genomics
Cypher Genomics is a leading genome informatics company offering a highly accurate, rapid and robust interpretation software solution for users of human genome sequencing. The proprietary, automated genomic interpretation platform allows clinical laboratories to tune Cypher Genomics’ market leading sensitivity and specificity profiles to develop molecular tests for diagnostic and prognostic use and pharmaceutical companies to discover biomarkers from genome sequence data in sample sizes typical of early stage drug development studies. Through Mantis, the genome interpretation software as a service offering, and Coral, a biomarker discovery service, Cypher Genomics can improve health care and reduce costs by facilitating improved diagnostic accuracy and earlier interventions, optimizing therapeutic approaches and reducing adverse drug reactions. Cypher Genomics is located in San Diego, California.

For more information about Cypher Genomics, visit www.cyphergenomics.com and connect with us on Twitter @cyphergenomics.

Forward Looking Statements
Statements contained in this press release regarding matters that are not historical facts are “forward-looking statements” within the meaning of the Private Securities Litigation Reform Act of 1995. Because such statements are subject to risks and uncertainties, actual results may differ materially from those expressed or implied by such forward-looking statements. Risks are described more fully in Sequenom’s filings with the Securities and Exchange Commission, including without limitation Sequenom’s most recent Quarterly Report on Form 10-Q and other documents subsequently filed with or furnished to the Securities and Exchange Commission. All forward-looking statements contained in this press release speak only as of the date on which they were made. Sequenom undertakes no obligation to update such statements to reflect events that occur or circumstances that exist after the date on which they were made.

 

Logo: http://photos.prnewswire.com/prnh/20150121/170618LOGO

Logo: http://photos.prnewswire.com/prnh/20040415/SQNMLOGO

 

SOURCE Sequenom, Inc.

Medical Specialist, Cardiometabolic (MS) – Southern CA (San Diego, CA)

January 22, 2015 – 4:13 am | Edit Post
Medical Specialist, Cardiometabolic (MS) – Southern CA (San Diego, CA)

CA-San Diego, Medical Specialist, Cardiometabolic (MS) – Southern CA (San Diego, CA) San Diego, CA Requisition Number: 2564 JOB DESCRIPTION: Regeneron continues to grow, build and invest as we pursue our mission to turn science into medicines that help…